Cayman Pharma was established in October of 2006 by the merger of two companies with very different geographical origins. Both, however, had unparalleled experience and expertise in prostaglandin chemistry. One was Cayman Chemical Inc., a research biochemical company with global recognition as an expert in the field of lipid chemistry. It was established in 1980 with the vision that was achieved in full, to demonstrate to potential customers that naturally occurring prostaglandins could be highly valued and versatile raw material. Cayman was soon selling a wide variety of extremely pure and valuable prostaglandin standards, especially to customers from research & development. The other was NeraPharm, a company located within the Spolana complex north of Prague since the late 1970s. Their goal, which was largely achieved, was to implement independent production of important veterinary prostaglandins for the entire Eastern Europe block. Cayman Pharma s.r.o. was established after acquisition of NeraPharm by Cayman Chemical, and following the acquisition aimed primarily at prostaglandins used in human medicine.
Cayman Pharma represents the accumulation of almost 60 years of experience with prostaglandin synthesis. NeraPharm brings to the company a deep understanding of GMP manufacturing under US FDA and EMEA standards. Then provides also many years of experience supplying pharmaceutical grade active ingredients and tremendous boost in manufacturing capacity. Cayman Chemical Inc., on the other hand, brings cutting edge knowledge in the research of the most advanced prostaglandin compounds. Drug candidates of veterinary products for cattle oestrus synchronization and of humane products for more current indications such as glaucoma, male and female sexual dysfunction and pulmonary hypertension are all part of current portfolio of Cayman Pharma s.r.o.